Naoyuki Nishiya

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7935639/publications.pdf

Version: 2024-02-01

26 papers	1,605 citations	687363 13 h-index	610901 24 g-index
30 all docs	30 docs citations	30 times ranked	2627 citing authors

#	Article	IF	Citations
1	Ivermectin represses Wnt/Î²-catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases. IScience, 2022, 25, 103912.	4.1	4
2	Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Cancer Science, 2021, 112, 1963-1974.	3.9	13
3	Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant. Bioorganic and Medicinal Chemistry, 2021, 34, 116039.	3.0	6
4	Switching from Intravenous to Oral Tacrolimus Reduces its Blood Concentration in Paediatric Cancer Patients. Anticancer Research, 2021, 41, 2591-2596.	1.1	0
5	Domestication of chemicals attacking metazoan embryogenesis: identification of safe natural products modifying developmental signaling pathways in human. Journal of Antibiotics, 2021, 74, 651-659.	2.0	0
6	IMU1003, an atrarate derivative, inhibits Wnt/Î²-catenin signaling. Biochemical and Biophysical Research Communications, 2020, 532, 440-445.	2.1	5
7	Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling. Pharmaceuticals, 2019, 12, 165.	3.8	1
8	Clotrimazole inhibits the Wnt/Î²-catenin pathway by activating two eIF2Î± kinases: The heme-regulated translational inhibitor and the double-stranded RNA-induced protein kinase. Biochemical and Biophysical Research Communications, 2018, 506, 183-188.	2.1	4
9	Augmentation of the therapeutic efficacy of <scp>WEE</scp>1 kinase inhibitor <scp>AZD</scp>1775 by inhibiting the <scp>YAP</scp>â€“E2F1â€“<scp>DNA</scp> damage response pathway axis. FEBS Open Bio, 2018, 8, 1001-1012.	2.3	18
10	Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation. Anticancer Research, 2018, 38, 3471-3476.	1.1	8
11	Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant. Bioorganic and Medicinal Chemistry, 2017, 25, 6563-6580.	3.0	24
12	Dynamic Phenotypic Transition of Breast Cancer Cells In Vitro Revealed by Self-floating Cell Culture. Anticancer Research, 2017, 37, 1793-1797.	1.1	0
13	Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio, 2015, 5, 542-549.	2.3	153
14	JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M. World Journal of Biological Chemistry, 2015, 6, 409.	4.3	8
15	A Zebrafish Chemical Suppressor Screening Identifies Small Molecule Inhibitors of the Wnt/Î²-catenin Pathway. Chemistry and Biology, 2014, 21, 530-540.	6.0	37
16	Multimodal Effects of Small Molecule ROCK and LIMK Inhibitors on Mitosis, and Their Implication as Anti-Leukemia Agents. PLoS ONE, 2014, 9, e92402.	2.5	17
17	Chemical Modifier Screenings as Methods for Identifying Pathway-Targeting Compounds and for Predicting Drug-Drug Interactions. , 2014, 03, .		1
18	Identification of LY83583 as a specific inhibitor of Candida albicans MPS1 protein kinase. Biochemical and Biophysical Research Communications, 2011, 409, 418-423.	2.1	5

#	Article	IF	Citations
19	Slit2â€“Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nature Cell Biology, 2009, 11, 1325-1331.	10.3	195
20	Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nature Medicine, 2008, 14, 448-453.	30.7	346
21	Small-molecule synergist of the Wnt/Î²-catenin signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7444-7448.	7.1	118
22	An Î±4 integrinâ€“paxillinâ€“Arf-GAP complex restricts Rac activation to the leading edge of migrating cells. Nature Cell Biology, 2005, 7, 343-352.	10.3	200
23	CD98hc (SLC3A2) mediates integrin signaling. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 355-360.	7.1	224
24	Hic-5 Interacts with GIT1 with a Different Binding Mode from Paxillin. Journal of Biochemistry, 2002, 132, 279-289.	1.7	38
25	Hic-5-Reduced Cell Spreading on Fibronectin: Competitive Effects between Paxillin and Hic-5 through Interaction with Focal Adhesion Kinase. Molecular and Cellular Biology, 2001, 21, 5332-5345.	2.3	91
26	Hic-5, a Paxillin Homologue, Binds to the Protein-tyrosine Phosphatase PEST (PTP-PEST) through Its LIM 3 Domain. Journal of Biological Chemistry, 1999, 274, 9847-9853.	3.4	79